Show simple item record

dc.contributor.authorBen Ali, Walid
dc.contributor.authorVoisine, Pierre
dc.contributor.authorOlsen, Peter Skov
dc.contributor.authorJeanmart, Hugues
dc.contributor.authorNoiseux, Nicolas
dc.contributor.authorGoeken, Tracy
dc.contributor.authorSatishchandran, Vilas
dc.contributor.authorCademartiri, Filippo
dc.contributor.authorCutter, Garry
dc.contributor.authorVeerasingam, Dave
dc.contributor.authorBrown, Craig
dc.contributor.authorEmmert, Maximilian Y
dc.contributor.authorPerrault, Louis P
dc.date.accessioned2018-09-20T16:00:51Z
dc.date.available2018-09-20T16:00:51Z
dc.date.issued2018-04-01
dc.identifier.citationBen Ali, Walid; Voisine, Pierre; Olsen, Peter Skov; Jeanmart, Hugues; Noiseux, Nicolas; Goeken, Tracy; Satishchandran, Vilas; Cademartiri, Filippo; Cutter, Garry; Veerasingam, Dave; Brown, Craig; Emmert, Maximilian Y; Perrault, Louis P (2018). Duragraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial. Open Heart 5 (1),
dc.identifier.issn2053-3624
dc.identifier.urihttp://hdl.handle.net/10379/10402
dc.description.abstractIntroduction Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes neointimal hyperplasia that can advance to atherosclerosis characterised by SVG failure. This trial investigates the potential benefit of DuraGraft, a novel, one-time intraoperative graft treatment developed to efficiently protect the structural and functional integrity of the vascular endothelium, on the development and progression of VGD in CABG patients. Methods and analysis This ongoing prospective randomised, double-blinded multicentre trial (NCT02272582/NCT02774824) includes patients undergoing isolated CABG requiring at least two SVGs. It compares the impact of DuraGraft, a novel treatment against VGD versus the standard-of-care (SOC; heparinised saline) using a within-patient randomisation (with one SVG treated with DuraGraft and the other treated with SOC). Besides clinical assessments, patients undergo longitudinal 64-slice or better multidetector CT (MDCT) angiography of paired grafts (within each patient) at 4-6 weeks, 3 months and 12 months. Primary endpoints will be the magnitude of change in mean wall thickness and lumen diameter (stenosis) of paired grafts, at 3 and 12 months, respectively. Besides the evaluation of overall safety, longitudinal assessment of each graft (secondary endpoint) is performed in order to obtain insight into graft behaviour after CABG. Enrolment of 119 patients was successfully completed, and analysis of MDCT angiography follow-up is ongoing with the completed analysis becoming available by end of first quarter of 2018. Ethics and dissemination The regional ethics committees have approved the trial. Results will be submitted for publication.
dc.publisherBMJ
dc.relation.ispartofOpen Heart
dc.subjectsaphenous-vein grafts
dc.subjectinternal thoracic artery
dc.subjectcomputed-tomography
dc.subjectprevent iv
dc.subjectpatency
dc.subjectsurgery
dc.subjectfailure
dc.subjectstorage
dc.subjectangiography
dc.subjectguidelines
dc.titleDuragraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial
dc.typeArticle
dc.identifier.doi10.1136/openhrt-2018-000780
dc.local.publishedsourcehttps://openheart.bmj.com/content/5/1/e000780.full.pdf
nui.item.downloads0


Files in this item

This item appears in the following Collection(s)

Show simple item record